KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) EBITDA (2018 - 2025)

Historic EBITDA for Castle Biosciences (CSTL) over the last 8 years, with Q3 2025 value amounting to -$6.8 million.

  • Castle Biosciences' EBITDA fell 23396.34% to -$6.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$34.9 million, marking a year-over-year decrease of 326541.43%. This contributed to the annual value of $8.7 million for FY2024, which is 11275.43% up from last year.
  • As of Q3 2025, Castle Biosciences' EBITDA stood at -$6.8 million, which was down 23396.34% from -$4.3 million recorded in Q2 2025.
  • Castle Biosciences' 5-year EBITDA high stood at $5.1 million for Q3 2024, and its period low was -$31.5 million during Q1 2023.
  • In the last 5 years, Castle Biosciences' EBITDA had a median value of -$6.8 million in 2025 and averaged -$10.5 million.
  • As far as peak fluctuations go, Castle Biosciences' EBITDA plummeted by 118379.85% in 2023, and later soared by 17158.01% in 2024.
  • Quarter analysis of 5 years shows Castle Biosciences' EBITDA stood at -$6.4 million in 2021, then plummeted by 255.09% to -$22.8 million in 2022, then surged by 75.22% to -$5.7 million in 2023, then soared by 171.58% to $4.0 million in 2024, then tumbled by 268.0% to -$6.8 million in 2025.
  • Its last three reported values are -$6.8 million in Q3 2025, -$4.3 million for Q2 2025, and -$27.9 million during Q1 2025.